Abstract
Cancer pain is a critical factor affecting the quality of life for patients with advanced-stage malignancies. While opioids like morphine are standard clinical treatments, their potential to influence tumor progression remains controversial. This study investigates the expression of $\mu$ (MOR) and $\kappa$ (KOR) opioid receptors in hepatocellular carcinoma (HCC) and evaluates the effects of receptor-specific agonists on malignant phenotypes. We found that both KOR and MOR are highly expressed in HCC cell lines and tissues. Notably, the KOR-specific agonist U50488h and the mixed agonist oxycodone significantly inhibited HCC cell proliferation, colony formation, and migration, while inducing apoptosis. These effects were mediated by the activation of the PERK-mediated endoplasmic reticulum (ER) stress pathway. In contrast, the MOR-specific agonist morphine did not exhibit these anti-tumor effects. Our findings suggest that KOR-targeting opioids like U50488h offer a dual benefit of pain relief and tumor suppression, making them a promising choice for HCC management.
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Patients often suffer from severe pain in advanced stages, necessitating the use of opioids. However, the impact of traditional opioids like morphine on cancer progression is a subject of ongoing debate, with some evidence suggesting they may promote tumor growth. This research sought to identify an opioid that provides effective analgesia while simultaneously retarding cancer progression by comparing the effects of MOR-specific and KOR-specific agonists.
Methods and Materials
The researchers utilized a multi-disciplinary approach to validate their findings:
- Cellular Models: Human HCC cell lines (Hep3B, Huh7, HepG2, Bel 7402) were compared against a normal hepatocyte line (LO2).
- Molecular Analysis: RT-qPCR and Western Blotting quantified mRNA and protein expression of KOR, MOR, and ER stress markers (PERK, GRP78, CHOP).
- Phenotypic Assays: Cell viability (CCK-8), colony formation, wound healing (migration), and flow cytometry (apoptosis) measured the drugs' impact on cancer hallmarks.
- Pathway Validation: The PERK inhibitor GSK2656157 was used to confirm the role of the ER stress pathway.
- In Vivo Modeling: A xenograft mouse model (BALB/c nude mice) observed the effects of U50488h, oxycodone, and morphine on tumor volume and weight over 21 days.
- Human Tissue Samples: HCC and adjacent non-tumorous tissues were obtained from The First Affiliated Hospital of USTC to validate receptor expression levels.
Results
Receptor Overexpression in HCC
Initial assays confirmed that both KOR and MOR are significantly upregulated in HCC tissues and cell lines compared to healthy liver tissue. This overexpression establishes these receptors as viable therapeutic targets for HCC management.
KOR vs. MOR Divergence
While morphine (a MOR-specific agonist) had negligible effects on tumor growth, U50488h (KOR-specific) and oxycodone (mixed KOR/MOR) significantly inhibited malignant phenotypes. Specifically, treatment with 10 $\mu$M of U50488h or oxycodone significantly increased the apoptosis rate in Hep3B and Huh7 cells, a result not seen with morphine. Furthermore, KOR agonists significantly reduced the metastatic potential of HCC cells by inhibiting the Epithelial-Mesenchymal Transition (EMT).
The ER Stress Mechanism
The study identified that KOR activation triggers the "Unfolded Protein Response" (UPR) via the PERK signaling pathway. When this stress is enhanced by KOR agonists, it shifts from a survival mechanism to a pro-apoptotic signal, increasing levels of CHOP and Caspase-3. The use of the PERK inhibitor GSK2656157 partially reversed the apoptosis induced by U50488h, confirming that the PERK pathway is a primary mediator of KOR-induced cell death.
In Vivo Tumor Suppression
In the mouse xenograft model, U50488h and oxycodone significantly reduced tumor weight and volume compared to the control group. Morphine showed no significant inhibitory effect on tumor growth, reinforcing the conclusion that anti-cancer benefits are specifically tied to KOR activation.
Discussion and Future Work
While the study successfully demonstrated the anti-tumor potential of KOR agonists, some limitations remain. The PERK inhibitor did not completely block the effects of the KOR agonist, suggesting that other signaling pathways, such as ERK/MAPK, might also be involved. Additionally, while oxycodone is already in clinical use, U50488h is currently a research tool. Future clinical studies are required to determine if the dosages necessary for anti-tumor effects in humans are safe and provide adequate pain relief. Further research should also explore the specific crosstalk between G-protein signaling and ER calcium homeostasis that leads to PERK upregulation.
Summary updated